
<!DOCTYPE html>
<html>
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta http-equiv="X-UA-Compatible" content="ie=edge">
<title>Markmap</title>
<style>
* {
  margin: 0;
  padding: 0;
}
#mindmap {
  display: block;
  width: 100vw;
  height: 100vh;
}
</style>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/style.css">
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.16.8/dist/katex.min.css">
</head>
<body>
<svg id="mindmap"></svg>
<script src="https://cdn.jsdelivr.net/npm/d3@7.8.5/dist/d3.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-view@0.17.0/dist/browser/index.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/index.js"></script>
<script>
window.WebFontConfig = {
  custom: {
    families: [
      "KaTeX_AMS","KaTeX_Caligraphic:n4,n7","KaTeX_Fraktur:n4,n7",
      "KaTeX_Main:n4,n7,i4,i7","KaTeX_Math:i4,i7","KaTeX_Script",
      "KaTeX_SansSerif:n4,n7,i4","KaTeX_Size1","KaTeX_Size2",
      "KaTeX_Size3","KaTeX_Size4","KaTeX_Typewriter"
    ],
    active: function() {
      window.markmap.refreshHook.call();
    }
  }
};
</script>
<script src="https://cdn.jsdelivr.net/npm/webfontloader@1.6.28/webfontloader.js" defer></script>
<script>
(() => {
  setTimeout(() => {
    const { markmap: Markmap, mm: markmapInstance } = window;
    const toolbar = new Markmap.Toolbar();
    toolbar.attach(markmapInstance);
    const toolbarElement = toolbar.render();
    toolbarElement.style.position = 'absolute';
    toolbarElement.style.bottom = '20px';
    toolbarElement.style.right = '20px';
    document.body.append(toolbarElement);
  });

  ((getMarkmap, getOptions, root, jsonOptions) => {
    const markmap = getMarkmap();
    window.mm = markmap.Markmap.create(
      "svg#mindmap",
      (getOptions || markmap.deriveOptions)(jsonOptions),
      root
    );
  })(() => window.markmap, null, {"content":"BCM Breast Cancer Trials","children":[{"content":"MED ONC","children":[{"content":"Adjuvant","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"4,5\"><strong>LoTAM</strong></p>","children":[{"content":"\n<p data-lines=\"6,7\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage 1 and 2A (T &lt; 30mm, N0) ER+ (&gt;10%) HER2- Breast Cancer</p>","children":[],"payload":{"lines":"6,9"}},{"content":"\n<p data-lines=\"9,10\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> LOW Genomic risk (MP LOW, RS &lt;26 OR ProSigna &lt;40)</p>","children":[],"payload":{"lines":"9,10"}}],"payload":{"lines":"4,10"}}],"payload":{"lines":"3,10"}}],"payload":{"lines":"2,10"}},{"content":"HER2","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"12,13\"><strong>FLAMINGO -01</strong></p>","children":[{"content":"\n<p data-lines=\"14,15\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage I/II with nonpCR OR stage III (pCR or not) to be enorlled &lt;90 days from completion of HP/TDM1</p>","children":[],"payload":{"lines":"14,17"}},{"content":"\n<p data-lines=\"17,18\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TWO cohorst depending on HLA-A-02</p>","children":[],"payload":{"lines":"17,18"}}],"payload":{"lines":"12,18"}},{"content":"\n<p data-lines=\"18,19\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"20,21\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"20,23"}},{"content":"\n<p data-lines=\"23,24\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"23,24"}}],"payload":{"lines":"18,24"}},{"content":"\n<p data-lines=\"24,25\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"26,27"}}],"payload":{"lines":"24,27"}},{"content":"\n<p data-lines=\"27,28\">ADEPT</p>","children":[{"content":"\n<p data-lines=\"29,30\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ OR PR+ with HER2+ disease T1A/B/C. N1mi allowed.</p>","children":[],"payload":{"lines":"29,32"}},{"content":"\n<p data-lines=\"32,33\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No more than 8 weeks of ET</p>","children":[],"payload":{"lines":"32,33"}}],"payload":{"lines":"27,33"}}],"payload":{"lines":"11,33"}}],"payload":{"lines":"10,33"}},{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"35,36\"><strong>CAMBRIA-1</strong></p>","children":[{"content":"\n<p data-lines=\"37,38\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Intermediate and High risk to randomize between adjuvant year 2 : 5 to either continue adj. ET SoC vs oral SERD</p>","children":[],"payload":{"lines":"37,40"}},{"content":"\n<p data-lines=\"40,41\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Intermediate: T3 N0 | T1c/T2 N1 [2-3 LN] | T1c/T2 N0 (Grade III, KI67 &gt;= 20%, LumB/RS26, or prior chemotherapy)</p>","children":[],"payload":{"lines":"40,43"}},{"content":"\n<p data-lines=\"43,44\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> High: Stage III | T1c/T2 N1 [2-3]  (Grade III, KI67 &gt;= 20%, LumB/RS26) | T1c/T2 N1 [1/3] (Grade III, KI67 &gt;= 20%, LumB/RS26)</p>","children":[],"payload":{"lines":"43,44"}}],"payload":{"lines":"35,44"}},{"content":"\n<p data-lines=\"44,45\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"46,47\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"46,49"}},{"content":"\n<p data-lines=\"49,50\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"49,50"}}],"payload":{"lines":"44,50"}},{"content":"\n<p data-lines=\"50,51\"><strong>OFSET (NRG BR009)</strong></p>","children":[{"content":"\n<p data-lines=\"52,53\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ (&gt;1%) HER2- with pT1-3 pN0-1.</p>","children":[],"payload":{"lines":"52,55"}},{"content":"\n<p data-lines=\"55,56\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> RS N1 &lt;26. RS N0 21-25. RS N0 16-20 WITH T minimum at 30mm (G1), 20mm (G2) or 10mm (G3)</p>","children":[],"payload":{"lines":"55,56"}}],"payload":{"lines":"50,56"}},{"content":"\n<p data-lines=\"56,57\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"58,59"}}],"payload":{"lines":"56,59"}},{"content":"\n<p data-lines=\"59,60\">ELEGANT</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ High Risk (Defined by trial) between year 2 and 5 of adjuvant ET +/- CDK4/6i or PARPi","children":[],"payload":{"lines":"61,62"}}],"payload":{"lines":"59,62"}}],"payload":{"lines":"34,62"}}],"payload":{"lines":"33,62"}},{"content":"TNBC","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"64,65\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"66,67\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"66,69"}},{"content":"\n<p data-lines=\"69,70\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"69,70"}}],"payload":{"lines":"64,70"}},{"content":"\n<p data-lines=\"70,71\"><strong>OptimICE-PCR</strong></p>","children":[{"content":"\n<p data-lines=\"72,73\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC (ER/PR &lt;10%)  T1cN1-2 or T2-4N0-2 with ypT0 OR ypTis</p>","children":[],"payload":{"lines":"72,75"}},{"content":"\n<p data-lines=\"75,76\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adju RT  and Pembro, followed by registration</p>","children":[],"payload":{"lines":"75,76"}}],"payload":{"lines":"70,76"}},{"content":"\n<p data-lines=\"76,77\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"78,79"}}],"payload":{"lines":"76,79"}}],"payload":{"lines":"63,79"}}],"payload":{"lines":"62,79"}}],"payload":{"lines":"1,79"}},{"content":"Metastatic","children":[{"content":"HER2","children":[{"content":"2","children":[{"content":"\n<p data-lines=\"82,83\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"84,85\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"84,87"}},{"content":"\n<p data-lines=\"87,88\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"87,88"}}],"payload":{"lines":"82,88"}}],"payload":{"lines":"81,88"}},{"content":"3","children":[{"content":"\n<p data-lines=\"89,90\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"91,92\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"91,94"}},{"content":"\n<p data-lines=\"94,95\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"94,95"}}],"payload":{"lines":"89,95"}}],"payload":{"lines":"88,95"}},{"content":"4","children":[{"content":"\n<p data-lines=\"96,97\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"98,99\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"98,101"}},{"content":"\n<p data-lines=\"101,102\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"101,102"}}],"payload":{"lines":"96,102"}}],"payload":{"lines":"95,102"}}],"payload":{"lines":"80,102"}},{"content":"HR POS","children":[{"content":"1","children":[{"content":"\n<p data-lines=\"104,105\"><strong>EvoPAR-Breast01</strong></p>","children":[{"content":"\n<p data-lines=\"106,107\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> DenoVo metastatic opr 1ry resistant ER+ (&gt;1%)</p>","children":[],"payload":{"lines":"106,109"}},{"content":"\n<p data-lines=\"109,110\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> BRCA1/2 OR PALB2 (either germline or somatic)</p>","children":[],"payload":{"lines":"109,110"}}],"payload":{"lines":"104,110"}}],"payload":{"lines":"103,110"}},{"content":"2","children":[{"content":"\n<p data-lines=\"111,112\"><strong>ELAINE-III</strong></p>","children":[{"content":"\n<p data-lines=\"113,114\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Progression on 1st Line CDK4/6. ESR1 mutation</p>","children":[],"payload":{"lines":"113,116"}},{"content":"\n<p data-lines=\"116,117\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No priot Abema in adjuvant or metastatic setting</p>","children":[],"payload":{"lines":"116,117"}}],"payload":{"lines":"111,117"}},{"content":"\n<p data-lines=\"117,118\"><strong>OPERA-1</strong></p>","children":[{"content":"\n<p data-lines=\"119,120\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Post 1st Line progression while on ET/CDK , adjuvant ET or within 2 years post ET. No prior Chemo in Stage 4.</p>","children":[],"payload":{"lines":"119,122"}},{"content":"\n<p data-lines=\"122,123\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]</p>","children":[],"payload":{"lines":"122,123"}}],"payload":{"lines":"117,123"}},{"content":"\n<p data-lines=\"123,124\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"125,126\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"125,128"}},{"content":"\n<p data-lines=\"128,129\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"128,129"}}],"payload":{"lines":"123,129"}},{"content":"\n<p data-lines=\"129,130\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"131,132\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"131,134"}},{"content":"\n<p data-lines=\"134,135\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ HER2- must have progressed on or within 12 months of adjuvant ET, OR got minimum of 1L of ET (including prior CDK4/6)</p>","children":[],"payload":{"lines":"134,135"}}],"payload":{"lines":"129,135"}},{"content":"\n<p data-lines=\"135,136\">QuantifyHER</p>","children":[{"content":"\n<p data-lines=\"137,138\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"137,140"}},{"content":"\n<p data-lines=\"140,141\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible</p>","children":[],"payload":{"lines":"140,141"}}],"payload":{"lines":"135,141"}}],"payload":{"lines":"110,141"}},{"content":"3","children":[{"content":"\n<p data-lines=\"142,143\"><strong>OPERA-1</strong></p>","children":[{"content":"\n<p data-lines=\"144,145\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Post 2 Lines Line of ET, lasting at least 6 months. No prior Chemo in Stage 4.</p>","children":[],"payload":{"lines":"144,147"}},{"content":"\n<p data-lines=\"147,148\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]</p>","children":[],"payload":{"lines":"147,150"}},{"content":"\n<p data-lines=\"150,151\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If 2nd line was Faslo, 3rd line SoC can be AI</p>","children":[],"payload":{"lines":"150,151"}}],"payload":{"lines":"142,151"}},{"content":"\n<p data-lines=\"151,152\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"153,154\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"153,156"}},{"content":"\n<p data-lines=\"156,157\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"156,157"}}],"payload":{"lines":"151,157"}},{"content":"\n<p data-lines=\"157,158\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"159,160\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"159,162"}},{"content":"\n<p data-lines=\"162,163\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received 1st Line ET (including CDK4/6i), 2nd Line,</p>","children":[],"payload":{"lines":"162,163"}}],"payload":{"lines":"157,163"}},{"content":"\n<p data-lines=\"163,164\">QuantifyHER</p>","children":[{"content":"\n<p data-lines=\"165,166\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"165,168"}},{"content":"\n<p data-lines=\"168,169\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible</p>","children":[],"payload":{"lines":"168,169"}}],"payload":{"lines":"163,169"}}],"payload":{"lines":"141,169"}},{"content":"4","children":[{"content":"\n<p data-lines=\"170,171\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"172,173\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"172,175"}},{"content":"\n<p data-lines=\"175,176\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"175,176"}}],"payload":{"lines":"170,176"}},{"content":"\n<p data-lines=\"176,177\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"178,179\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"178,181"}},{"content":"\n<p data-lines=\"181,182\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received 1st Line ET (including CDK4/6i), 2nd Line, and on 3rd Line ADC. Can join directly to ADC2 at 4th L from Dato or Enhertu</p>","children":[],"payload":{"lines":"181,182"}}],"payload":{"lines":"176,182"}},{"content":"\n<p data-lines=\"182,183\">QuantifyHER</p>","children":[{"content":"\n<p data-lines=\"184,185\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"184,187"}},{"content":"\n<p data-lines=\"187,188\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible</p>","children":[],"payload":{"lines":"187,188"}}],"payload":{"lines":"182,188"}}],"payload":{"lines":"169,188"}}],"payload":{"lines":"102,188"}},{"content":"TNBC","children":[{"content":"1","children":[{"content":"\n<p data-lines=\"190,191\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"192,193"}}],"payload":{"lines":"190,193"}},{"content":"\n<p data-lines=\"193,194\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"195,196\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"195,198"}},{"content":"\n<p data-lines=\"198,199\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Strict 0-1 prior lines.</p>","children":[],"payload":{"lines":"198,199"}}],"payload":{"lines":"193,199"}}],"payload":{"lines":"189,199"}},{"content":"2","children":[{"content":"\n<p data-lines=\"200,201\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"202,203\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"202,205"}},{"content":"\n<p data-lines=\"205,206\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"205,206"}}],"payload":{"lines":"200,206"}},{"content":"\n<p data-lines=\"206,207\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"208,209"}}],"payload":{"lines":"206,209"}},{"content":"\n<p data-lines=\"209,210\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"211,212\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"211,214"}},{"content":"\n<p data-lines=\"214,215\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Strict 0-1 prior lines, but can join from Enhertu 2L to Dato</p>","children":[],"payload":{"lines":"214,215"}}],"payload":{"lines":"209,215"}},{"content":"\n<p data-lines=\"215,216\">QuantifyHER</p>","children":[{"content":"\n<p data-lines=\"217,218\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER- IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"217,220"}},{"content":"\n<p data-lines=\"220,221\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible\"</p>","children":[],"payload":{"lines":"220,221"}}],"payload":{"lines":"215,221"}}],"payload":{"lines":"199,221"}},{"content":"3","children":[{"content":"\n<p data-lines=\"222,223\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"224,225\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"224,227"}},{"content":"\n<p data-lines=\"227,228\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"227,228"}}],"payload":{"lines":"222,228"}},{"content":"\n<p data-lines=\"228,229\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"230,231"}}],"payload":{"lines":"228,231"}},{"content":"\n<p data-lines=\"231,232\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"233,234\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"233,236"}},{"content":"\n<p data-lines=\"236,237\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Strict 0-1 prior lines, but can join from Enhertu 2L to Dato</p>","children":[],"payload":{"lines":"236,237"}}],"payload":{"lines":"231,237"}},{"content":"\n<p data-lines=\"237,238\">QuantifyHER</p>","children":[{"content":"\n<p data-lines=\"239,240\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER- IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"239,242"}},{"content":"\n<p data-lines=\"242,243\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible\"</p>","children":[],"payload":{"lines":"242,243"}}],"payload":{"lines":"237,243"}}],"payload":{"lines":"221,243"}},{"content":"4","children":[{"content":"\n<p data-lines=\"244,245\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"246,247\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"246,249"}},{"content":"\n<p data-lines=\"249,250\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"249,250"}}],"payload":{"lines":"244,250"}}],"payload":{"lines":"243,250"}}],"payload":{"lines":"188,250"}}],"payload":{"lines":"79,250"}},{"content":"Neoadjuvant","children":[{"content":"HER2","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"253,254\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"255,256\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"255,258"}},{"content":"\n<p data-lines=\"258,259\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Will receive weekly Taxol HP  with ddAC</p>","children":[],"payload":{"lines":"258,259"}}],"payload":{"lines":"253,259"}},{"content":"\n<p data-lines=\"259,260\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"261,262\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"261,264"}},{"content":"\n<p data-lines=\"264,265\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"264,265"}}],"payload":{"lines":"259,265"}},{"content":"\n<p data-lines=\"265,266\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"267,268"}}],"payload":{"lines":"265,268"}}],"payload":{"lines":"252,268"}}],"payload":{"lines":"251,268"}},{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"270,271\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"272,273\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"272,275"}},{"content":"\n<p data-lines=\"275,276\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> High Risk ER+ (Grade III, Age &lt;50, ER &lt; 6/8 OR Ki67 &gt;29%). Will receive weekly Taxol with ddAC</p>","children":[],"payload":{"lines":"275,276"}}],"payload":{"lines":"270,276"}},{"content":"\n<p data-lines=\"276,277\"><strong>EVANGELINE</strong></p>","children":[{"content":"\n<p data-lines=\"278,279\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Clinical T2 or T3 and N0 or N1 with Grade I and II</p>","children":[],"payload":{"lines":"278,281"}},{"content":"\n<p data-lines=\"281,282\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ 67% or more, Allred 6-8</p>","children":[],"payload":{"lines":"281,282"}}],"payload":{"lines":"276,282"}},{"content":"\n<p data-lines=\"282,283\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"284,285\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"284,287"}},{"content":"\n<p data-lines=\"287,288\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"287,288"}}],"payload":{"lines":"282,288"}},{"content":"\n<p data-lines=\"288,289\">NCBRE</p>","children":[{"content":"\n<p data-lines=\"290,291\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ILC ER+ PR+ HER2- with ERBB2 mutation.</p>","children":[],"payload":{"lines":"290,293"}},{"content":"\n<p data-lines=\"293,294\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1c (Min size 15mm) N0/N1/N2</p>","children":[],"payload":{"lines":"293,294"}}],"payload":{"lines":"288,294"}},{"content":"\n<p data-lines=\"294,295\"><strong>S2206</strong></p>","children":[{"content":"\n<p data-lines=\"296,297\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage II and III, including IBC. ER+ or PR+ per CAP (&gt;1%)</p>","children":[],"payload":{"lines":"296,299"}},{"content":"\n<p data-lines=\"299,300\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> High 2 on MP</p>","children":[],"payload":{"lines":"299,300"}}],"payload":{"lines":"294,300"}},{"content":"\n<p data-lines=\"300,301\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"302,303"}}],"payload":{"lines":"300,303"}}],"payload":{"lines":"269,303"}}],"payload":{"lines":"268,303"}},{"content":"TNBC","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"305,306\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"307,308\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"307,310"}},{"content":"\n<p data-lines=\"310,311\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Will receive weekly Taxol with ddAC (Pembro added if indicated, Carbo added if T3)</p>","children":[],"payload":{"lines":"310,311"}}],"payload":{"lines":"305,311"}},{"content":"\n<p data-lines=\"311,312\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"313,314\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"313,316"}},{"content":"\n<p data-lines=\"316,317\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"316,317"}}],"payload":{"lines":"311,317"}},{"content":"\n<p data-lines=\"317,318\"><strong>S2212</strong></p>","children":[{"content":"\n<p data-lines=\"319,320\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC (ER/PR &lt;5%) with T2-T4 N0 OR T1-T3 N1-N2. Randomized to either KN522 versus Taxotere Carbo  Pembro x 6 Cycles</p>","children":[],"payload":{"lines":"319,322"}},{"content":"\n<p data-lines=\"322,323\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No Stage IIIC, IIIB T4 N+ OR IBC</p>","children":[],"payload":{"lines":"322,323"}}],"payload":{"lines":"317,323"}},{"content":"\n<p data-lines=\"323,324\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"325,326"}}],"payload":{"lines":"323,326"}},{"content":"\n<p data-lines=\"326,327\"><strong>TNBC ctDNA Tissue Banking</strong></p>","children":[{"content":"\n<p data-lines=\"328,329\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Stage II/III receiving NACT (+/- ICB)</p>","children":[],"payload":{"lines":"328,331"}},{"content":"\n<p data-lines=\"331,332\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ctDNA collected after Taxol and after AC, both before definitive surgery</p>","children":[],"payload":{"lines":"331,332"}}],"payload":{"lines":"326,332"}}],"payload":{"lines":"304,332"}}],"payload":{"lines":"303,332"}}],"payload":{"lines":"250,332"}}],"payload":{"lines":"0,332"}},{"content":"RAD ONC","children":[{"content":"Adjuvant","children":[{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"336,337\"><strong>MA39</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Newly Diagnosis of IDC w/ no metastisis<br>\nTreated with BCS or Mastectomy with no residual disease","children":[],"payload":{"lines":"338,340"}}],"payload":{"lines":"336,340"}}],"payload":{"lines":"335,340"}}],"payload":{"lines":"334,340"}}],"payload":{"lines":"333,340"}},{"content":"Postsurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"343,344\">PREDICT II</p>","children":[{"content":"\n<p data-lines=\"345,346\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dx of DCIS w/ tumor size &lt;6cm</p>","children":[],"payload":{"lines":"345,348"}},{"content":"\n<p data-lines=\"348,349\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Eligible for BCS, radiation and/or systemic treatment</p>","children":[],"payload":{"lines":"348,349"}}],"payload":{"lines":"343,349"}}],"payload":{"lines":"342,349"}}],"payload":{"lines":"341,349"}}],"payload":{"lines":"340,349"}}],"payload":{"lines":"332,349"}},{"content":"SURG ONC","children":[{"content":"Peri-Surgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"353,354\"><strong>CHEST</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Undergoing Mastectomy + Reconstruction","children":[],"payload":{"lines":"355,356"}}],"payload":{"lines":"353,356"}},{"content":"\n<p data-lines=\"356,357\"><strong>Breast ATLAS</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Undergoing PPX Mastectomy","children":[],"payload":{"lines":"358,359"}}],"payload":{"lines":"356,359"}},{"content":"\n<p data-lines=\"359,360\"><strong>PRECISION</strong></p>","children":[{"content":"\n<p data-lines=\"361,362\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dx of DCIS and/or IDC undergoing BCS or mastectomy</p>","children":[],"payload":{"lines":"361,364"}},{"content":"\n<p data-lines=\"364,365\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No hx of prior therapy treatment</p>","children":[],"payload":{"lines":"364,365"}}],"payload":{"lines":"359,365"}},{"content":"\n<p data-lines=\"365,366\"><strong>SentiNot 2.0</strong></p>","children":[{"content":"\n<p data-lines=\"367,368\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pre-operative diagnosis of DCIS or other suspicious lesion not confirmed to be invasive breast cancer</p>","children":[],"payload":{"lines":"367,370"}},{"content":"\n<p data-lines=\"370,371\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Willing to forgo initial SLNB and have SLNB as a later second procedure if DCIS is upgraded to invasive cancer</p>","children":[],"payload":{"lines":"370,371"}}],"payload":{"lines":"365,371"}},{"content":"\n<p data-lines=\"371,372\"><strong>Magellan</strong></p>","children":[{"content":"\n<p data-lines=\"373,374\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Non-metastatic patients with node positive breast cancer (cT0-4, N1)</p>","children":[],"payload":{"lines":"373,376"}},{"content":"\n<p data-lines=\"376,377\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Magseed placement prior to NAC</p>","children":[],"payload":{"lines":"376,377"}}],"payload":{"lines":"371,377"}}],"payload":{"lines":"352,377"}}],"payload":{"lines":"351,377"}}],"payload":{"lines":"350,377"}},{"content":"Postsurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"380,381\"><strong>LoTAM</strong></p>","children":[{"content":"\n<p data-lines=\"382,383\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage 1 and 2A (T &lt; 30mm, N0) ER+ (&gt;10%) HER2- Breast Cancer</p>","children":[],"payload":{"lines":"382,385"}},{"content":"\n<p data-lines=\"385,386\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> LOW Genomic risk (MP LOW, RS &lt;26 OR ProSigna &lt;40)</p>","children":[],"payload":{"lines":"385,386"}}],"payload":{"lines":"380,386"}}],"payload":{"lines":"379,386"}}],"payload":{"lines":"378,386"}}],"payload":{"lines":"377,386"}},{"content":"Presurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"389,390\"><strong>ATUSA-iSONO</strong></p>","children":[{"content":"\n<p data-lines=\"391,392\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Women with a suspected breast lesion in one of both breasts</p>","children":[],"payload":{"lines":"391,394"}},{"content":"\n<p data-lines=\"394,395\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Disease T1c or larger</p>","children":[],"payload":{"lines":"394,395"}}],"payload":{"lines":"389,395"}},{"content":"\n<p data-lines=\"395,396\"><strong>BCM TISSUE COLLECTION</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Suspicious lesion receiving an U/S guided biopsy with birads 4b-5","children":[],"payload":{"lines":"397,398"}}],"payload":{"lines":"395,398"}},{"content":"\n<p data-lines=\"398,399\"><strong>ANGEL</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Any suspicious lesion receiving a biopsy","children":[],"payload":{"lines":"400,401"}}],"payload":{"lines":"398,401"}}],"payload":{"lines":"388,401"}}],"payload":{"lines":"387,401"}}],"payload":{"lines":"386,401"}}],"payload":{"lines":"349,401"}}],"payload":{"lines":"0,401"}}, {"initialExpandLevel":4,"maxWidth":250});
})();
</script>
</body>
</html>
